Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?

6
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System

This question is a tough one, and the multidisciplinary teams I work with are still trying to figure it out. This is mostly because only 13% (67/501) of randomized participants in the Lung ART study received neoadjuvant chemotherapy, and 0% received neoadjuvant chemoimmunotherapy; all had pN2 or ypN...

Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?

2
1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Legacy Health System

Do you recommend adjuvant treatment for nodal isolated tumor cells in endometrial cancer?No, I don’t recommend adjuvant treatment for endometrial cancer patients based on the presence of isolated tumor cells (ITCs) alone, in the absence of other poor prognostic factors. A recent survey on sentinel l...

Will you continue anti-estrogen therapy in the setting of initiation of TDM-1 for patients with metastatic ER+/HER2+ breast cancer?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

The answer to this question has not been well studied, but the registration trials that led to the approval of T-DM1 (EMILIA and TH3RESA) did not use T-DM1 with concurrent hormonal therapy. Historically, we have avoided combining chemotherapy with hormonal therapy for breast cancer. This was in part...

For a relapsed AML patient who has previously received 7+3 followed by HIDAC consolidation, how do you choose between FLAG-IDA or MEC re-induction?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Roswell Park Cancer Center

In general, there is no "optimal" intensive salvage regimen for relapsed/refractory AML failing prior 7+3 and HIDAC consolidation. Prior comparisons of cytotoxic regimens have demonstrated no clear "winner" so it is based partly on clinical experience. At our center, I tend to prefer adding cladribi...

For a relapsed AML patient who has previously received 7+3 followed by HIDAC consolidation, how do you choose between FLAG-IDA or MEC re-induction?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Roswell Park Cancer Center

In general, there is no "optimal" intensive salvage regimen for relapsed/refractory AML failing prior 7+3 and HIDAC consolidation. Prior comparisons of cytotoxic regimens have demonstrated no clear "winner" so it is based partly on clinical experience. At our center, I tend to prefer adding cladribi...

Do you recommend treatment for CLL patients with biopsy proven infiltrative lesions in the liver without hepatic dysfunction or hepatomegaly?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · UPMC Hillman Cancer Center

This is a very difficult question without context of why the biopsy of the liver was done. In general, for virtually all body sites, when CLL is found as an asymptomatic surprise finding, I continue observation. This is particularly true when it is an area of high disease presence at the time of aut...

Do you recommend treatment for CLL patients with biopsy proven infiltrative lesions in the liver without hepatic dysfunction or hepatomegaly?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · UPMC Hillman Cancer Center

This is a very difficult question without context of why the biopsy of the liver was done. In general, for virtually all body sites, when CLL is found as an asymptomatic surprise finding, I continue observation. This is particularly true when it is an area of high disease presence at the time of aut...

Can tacrolimus in a transplant patient be used during radiation and concurrent chemoradiation?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · OSUCCC – James

Patients with solid organ transplants present unique challenges in management and risk of infectious complications, among others. The short answer is that tacrolimus can be used in the lowest dose possible, along with concurrent chemoradiation and close coordination with the transplant team. If the ...

Are there special considerations when treating a patient with sarcomatoid SCC of the head and neck?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Wake Forest School of Medicine

Sarcomatoid HNSCC is generally considered a less uncommon but more aggressive version of conventional HNSCC, thought to be at least in part arise as de-differentiated high-grade SCC. While they have been reported in some small studies to arise within a previously irradiated region, these epithelial ...

Do you routinely evaluate for PE if a DVT is found?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Jacksonville

I would not routinely evaluate for PE in a patient with new DVT, unless they had symptoms or signs suggestive of PE diagnosis. But I would usually evaluate for DVT in a new PE patient. This is in case the patient develops leg swelling or pain in the future and DVT is found then. It's difficult, oc...